{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:50:19Z","timestamp":1772229019274,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ejca.2017.09.026","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T13:45:25Z","timestamp":1508161525000},"page":"205-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Immune checkpoint inhibitor\u2013associated CNS autoimmune\u00a0disorder (ICICAD)\u00a0following nivolumab treatment: A\u00a0new entity of drug-induced autoimmune encephalitis?"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1344-7499","authenticated-orcid":false,"given":"Herwig","family":"Strik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Keber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasim Alhaj","family":"Hammoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Riera-Knorrenschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Carl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Dodel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Pagenstecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.09.026_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.09.026_bib2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1634\/theoncologist.2015-0507","article-title":"FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2017.09.026_bib3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.seminoncol.2015.05.013","article-title":"Antagonists of PD-1 and PD-L1 in cancer treatment","volume":"42","author":"Lipson","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2017.09.026_bib4","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2017.09.026_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2017.09.026_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1515584","article-title":"Pembrolizumab-induced demyelinating polyradiculoneuropathy","volume":"375","author":"de Maleissye","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2017.09.026_bib7","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejca.2017.09.026_bib8","first-page":"1475","article-title":"Ipilimumab induced encephalitis: a case report","volume":"11","author":"Boyd","year":"2015","journal-title":"Immunome Res"},{"key":"10.1016\/j.ejca.2017.09.026_bib9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejca.2017.09.026_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3171\/2016.8.PEDS16326","article-title":"Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report","volume":"19","author":"Zhu","year":"2017","journal-title":"J Neurosurg Pediatr"},{"key":"10.1016\/j.ejca.2017.09.026_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2017.09.026_bib12","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00415-015-7694-7","article-title":"Acute disseminated encephalomyelitis: current controversies in diagnosis and outcome","volume":"262","author":"Koelman","year":"2015","journal-title":"J Neurol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917313072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917313072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T18:27:46Z","timestamp":1540492066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917313072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":12,"alternative-id":["S0959804917313072"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.09.026","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor\u2013associated CNS autoimmune\u00a0disorder (ICICAD)\u00a0following nivolumab treatment: A\u00a0new entity of drug-induced autoimmune encephalitis?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}